Mark Throsby

Mark Throsby

Company: Gadeta

Job title: Chief Scientific Officer


Exploiting Gamma Delta TCR Targeting to Enable Safe & Effective Cell Therapies for Solid Tumors 11:30 am

γδ TCR are naturally selected, recognize surface targets like antibodies on transformed “stressed” tumor tissue but not healthy tissue and are not HLA dependent Gadeta’s TEG platform (T-cells engineered with a defined γδ TCR) magnifies the potential therapeutic activity of γδ T-cells The talk will highlight Gadeta’s clinical and development programsRead more

day: Conference Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.